Bone health in glucocorticoid-treated childhood acute lymphoblastic leukemia

Crit Rev Oncol Hematol. 2021 Dec:168:103492. doi: 10.1016/j.critrevonc.2021.103492. Epub 2021 Oct 13.

Abstract

Glucocorticoids (GCs) are widely used in the treatment of childhood acute lymphoblastic leukemia (ALL), but their long-term use is also associated with bone-related morbidities. Among others, growth deficit, decreased bone mineral density (BMD) and increased fracture rate are well-documented and severely impact quality of life. Unfortunately, no efficient treatment for the management of bone health impairment in patients and survivors is currently available. The overall goal of this review is to discuss the existing data on how GCs impair bone health in pediatric ALL and attempts made to minimize these side effects.

Keywords: Acute lymphoblastic; Bone density; Child; Glucocorticoids; Leukemia; Quality of life.

Publication types

  • Review

MeSH terms

  • Bone Density
  • Child
  • Glucocorticoids* / adverse effects
  • Humans
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / epidemiology
  • Quality of Life
  • Survivors

Substances

  • Glucocorticoids